Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

aspart

aspart is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 16
News articles 0
Drug details — aspart
Class
—
Route
—
Patents
20
Programs
16
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

aspart is an FDA-listed pharmaceutical active ingredient.

Key facts

INN aspart

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. Faster-acting insulin aspart Phase 3 · Novo Nordisk A/S · Diabetes
  2. Insulin Degludec and Insulin Aspart Phase 3 · Sunshine Guojian Pharmaceutical · Diabetes
  3. Insulin degludec/insulin aspart Phase 3 · Novo Nordisk A/S · Diabetes
  4. L-ornithine-L-aspartate Phase 3 · Chinese Academy of · Decompensated Cirrhosis
  5. SPD465-303 Phase 3 · Takeda · Attention Deficit Disorder With Hyperactivity
  6. V00018PC303 Phase 3 · Pierre Fabre Medicament · Cessation of smoking
  7. WN43174 Phase 3 · HOFFMANN-LA ROCHE · NMDAR or LGI1 mediated autoimmune Encephalitis
  8. biphasic insulin aspart Phase 3 · Novo Nordisk A/S · Diabetes

Related patents

Browse patents

  1. US 11166924

    N-methyl-d-aspartate receptor allosteric modulators and methods for their use

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8937093

    Heterocyclic aspartyl protease inhibitors

    Expires Mon Jan 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8778980

    Heterocyclic aspartyl protease inhibitors

    Expires Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8722708

    Substituted isoindolines as aspartyl protease inhibitors

    Expires Mon May 08 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8691831

    Heterocyclic aspartyl protease inhibitors

    Expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8455497

    Inhibitors of aspartyl protease

    Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8242112

    Heterocyclic aspartyl protease inhibitors

    Expires Mon Aug 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8178513

    Heterocyclic aspartyl protease inhibitors

    Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7919523

    Inhibitors of aspartyl protease

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7608632

    Sulfonamide inhibitors of aspartyl protease

    Expires Mon Oct 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7592368

    Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors

    Expires Mon Sep 17 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7442718

    Inhibitors of aspartyl protease

    Expires Mon Oct 23 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7419967

    Sulfonamide inhibitors of aspartyl protease

    Expires Mon Aug 28 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7321063

    Sulfonamide inhibitors of aspartyl protease

    Expires Mon Jan 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7132420

    Aspartic protease inhibitors

    Expires Mon Nov 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7119105

    Methods for treating neurodegenerative disorders using aspartyl protease inhibitors

    Expires Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 6878728

    Inhibitors of aspartyl protease

    Expires Mon Apr 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  18. US 6838474

    Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors

    Expires Mon Dec 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  19. US 6720335

    Sulfonamide inhibitors of aspartyl protease

    Expires Mon Apr 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  20. US 6617350

    Inhibitors of aspartyl protease

    Expires Mon Sep 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is aspart?

aspart is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.